Question: What is the brand name of the injectable drug for type 2 diabetes that was marketed by a Danish multinational pharmaceutical company with a majority shareholder Novo Holdings A/S?
Sentence (from "Liraglutide"): In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.
Relevant evidence: No